ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5889-5894

  De Jong, Floris A ^a   Marsh, Sharon ^b   Mathijssen, Ron H J ^a   King, Cristi ^b   Verweij, Jaap ^a   Sparreboom, Alex ^c   McLeod, Howard L ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; DRUG METABOLITE; IRINOTECAN; XENOBIOTIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CAUCASIAN; DETOXIFICATION; DNA SEQUENCE; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG DISTRIBUTION; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; DRUG RESISTANCE, MULTIPLE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 4444381535     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0144     Document Type: Article

References (37)

1. Dean M. The human ATP-binding cassette (ABC) transporter superfamily. Bethesda, MD: National Library of Medicine; 2002.
2. Ejendal KF, Hrycyna CA. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 2002;3: 503-11.
3. Xu J, Liu Y, Bates SE, Zhang J-T. Human half ABC transporter ABCG2 (BCRP, MXR, ABCP) is not a homodimer. Proc Am Assoc Cancer Res 2004;45.
4. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-9.
5. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
6. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst (Bethesda) 2000;92:1651-6.
7. Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002;20: 2943-50.
8. Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 2000;922:188-94.
9. Nakatomi K, Yoshikawa M, Oka M, et al. Transport of 7-ethyl-10- hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001;288:827-32.
10. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63.
11. Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001;280:1216-23.
12. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64.
13. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002;99: 15649-54.
14. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1:611-6.
15. Backstrom G, Taipalensuu J, Melhus H, et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003;18:359-64.
16. Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003;13:19-28.
17. Morisaki K, Robey RW, Nadjem T, et al. The Q141K single-nucleotide polymorphism impacts the transporter activity of ABCG2. Proc Am Assoc Cancer Res 2004;45.
18. de Jonge MJ, Sparreboom A, Planting AS, et al. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 2000;18:187-94.
19. de Jonge MJ, Verweij J, de Bruijn P, et al. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 2000;18:195-203.
20. Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9:3246-53.
21. McLeod HL, Syvanen AC, Githang'a J, et al. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or Southwest Asian individuals. Pharmacogenetics 1998;8:195-9.
22. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999;8:367-70.
23. Sparreboom A, de Bruijn P, de Jonge MJ, et al. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 1998;712:225-35.
24. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002;20:3293-301.
25. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
26. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997;3:1261-6.
27. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001;19:1501-18.
28. Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 2003;10:41-9.
29. de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A. Flat-fixed dosing of irinotecan: feasibility and influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004;10: 4068-71.
30. Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002;20:4303-12.
31. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002;20:3122-9.
32. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-20.
33. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001;31: 687-99.
34. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
35. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Investig 1998; 101:847-54.
36. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
37. Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004;76:38-44.